Literature DB >> 24354762

A silent mutation in mabA confers isoniazid resistance on Mycobacterium tuberculosis.

Hiroki Ando1, Tohru Miyoshi-Akiyama, Shinya Watanabe, Teruo Kirikae.   

Abstract

Drug resistance in Mycobacterium tuberculosis (Mtb) is caused by mutations in restricted regions of the genome. Mutations in katG, the promoter region of the mabA-inhA operon, and inhA are those most frequently responsible for isoniazid (INH) resistance. Several INH-resistant (INH(r) ) Mtb clinical isolates without mutations in these regions have been described, however, indicating that there are as yet undetermined mechanisms of INH resistance. We identified the mabA(g609a) silent mutation in a significant number of INH(r)  Mtb clinical isolates without known INH resistance mutations. A laboratory strain, H37Rv, constructed with mabA(g609a) , was resistant to INH. We show here that the mabA(g609a) mutation resulted in the upregulation of inhA, a gene encoding a target for INH, converting the region adjacent to the mutation into an alternative promoter for inhA. The mabA(g609a) silent mutation results in a novel mechanism of INH resistance, filling in a missing piece of INH resistance in Mtb.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24354762     DOI: 10.1111/mmi.12476

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  24 in total

1.  Systematic Review of Mutations Associated with Isoniazid Resistance Points to Continuing Evolution and Subsequent Evasion of Molecular Detection, and Potential for Emergence of Multidrug Resistance in Clinical Strains of Mycobacterium tuberculosis.

Authors:  Siavash J Valafar
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

2.  Validation of Novel Mycobacterium tuberculosis Isoniazid Resistance Mutations Not Detectable by Common Molecular Tests.

Authors:  Justin L Kandler; Alexandra D Mercante; Tracy L Dalton; Matthew N Ezewudo; Lauren S Cowan; Scott P Burns; Beverly Metchock; Peter Cegielski; James E Posey
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

3.  A Mutation in the 16S rRNA Decoding Region Attenuates the Virulence of Mycobacterium tuberculosis.

Authors:  Shinya Watanabe; Kazunori Matsumura; Hiroki Iwai; Keiji Funatogawa; Yuji Haishima; Chie Fukui; Kayo Okumura; Masako Kato-Miyazawa; Masahito Hashimoto; Kanae Teramoto; Fumiko Kirikae; Tohru Miyoshi-Akiyama; Teruo Kirikae
Journal:  Infect Immun       Date:  2016-07-21       Impact factor: 3.441

4.  The predictability of molecular evolution during functional innovation.

Authors:  Diana Blank; Luise Wolf; Martin Ackermann; Olin K Silander
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-10       Impact factor: 11.205

5.  Isoniazid and Rifampin-Resistance Mutations Associated With Resistance to Second-Line Drugs and With Sputum Culture Conversion.

Authors:  Eleanor S Click; Ekaterina V Kurbatova; Heather Alexander; Tracy L Dalton; Michael P Chen; James E Posey; Julia Ershova; J Peter Cegielski
Journal:  J Infect Dis       Date:  2020-06-11       Impact factor: 5.226

6.  A Synonymous Mutation Upstream of the Gene Encoding a Weak-Link Enzyme Causes an Ultrasensitive Response in Growth Rate.

Authors:  Jamie P Kershner; Sean Yu McLoughlin; Juhan Kim; Andrew Morgenthaler; Christopher C Ebmeier; William M Old; Shelley D Copley
Journal:  J Bacteriol       Date:  2016-09-22       Impact factor: 3.490

7.  Fitness-compensatory mutations facilitate the spread of drug-resistant F15/LAM4/KZN and F28 Mycobacterium tuberculosis strains in KwaZulu-Natal, South Africa.

Authors:  Charissa C Naidoo; Manormoney Pillay
Journal:  J Genet       Date:  2017-09       Impact factor: 1.166

8.  Xpert MTB/XDR: a 10-Color Reflex Assay Suitable for Point-of-Care Settings To Detect Isoniazid, Fluoroquinolone, and Second-Line-Injectable-Drug Resistance Directly from Mycobacterium tuberculosis-Positive Sputum.

Authors:  Yuan Cao; Heta Parmar; David Alland; Soumitesh Chakravorty; Rajiv L Gaur; Deanna Lieu; Shobana Raghunath; Nova Via; Simone Battaglia; Daniela M Cirillo; Claudia Denkinger; Sophia Georghiou; Robert Kwiatkowski; David Persing
Journal:  J Clin Microbiol       Date:  2021-02-18       Impact factor: 5.948

9.  Molecular mechanism of the synergistic activity of ethambutol and isoniazid against Mycobacterium tuberculosis.

Authors:  Chen Zhu; Yu Liu; Lihua Hu; Min Yang; Zheng-Guo He
Journal:  J Biol Chem       Date:  2018-09-05       Impact factor: 5.157

Review 10.  Consequences of genomic diversity in Mycobacterium tuberculosis.

Authors:  Mireia Coscolla; Sebastien Gagneux
Journal:  Semin Immunol       Date:  2014-10-22       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.